January 2026 was marked by large fundraising rounds and the launch of several healthcare funds.
Corporate investments in biotech and pharmaceutical startups are on the upswing, with several companies recently launching healthcare-focused funds.
Corporate venture capital investors took part in $2bn worth of biotech and pharmaceutical startup funding rounds in January 2026, the fifth consecutive month in which CVC investments in the sector have totaled more than $1bn.
The second half of 2025 showed an uptick in monthly corporate-backed biopharmaceutical investments compared with the first half of 2025, when investments were more muted.
